Faculty Staff

Tan Soo Yong

MBBS, DipRCPath, FRCPath, DMJ (Path), DPhil (Oxon)
Associate Professor
Senior Consultant
National University Hospital

Head and Chief
Department of Pathology
National University of Singapore / National University Hospital
Tel: +65 6772 4300
Email: pattsy@nus.edu.sg


Joint appointments
Senior Principal Investigator, Institute of Cell and Molecular Biology (IMCB), A*STAR
Head, Advanced Molecular Pathology Laboratory, IMCB
Visiting Professor, University Malaya, Kuala Lumpur
Visiting Professor, Guangdong Academy of Medical Sciences and Guangdong Hospital, China
Senior Consultant, Regulatory Policy and Licensing Division, Ministry of Health, Singapore
Senior Consultant, Manpower Development and Professional Standards Division, Ministry of Health, Singapore


Professional appointments
International Advisor (West Pacific), the Royal College of Pathologists
Member, International Lymphoma Study Group (ILSG)
Visiting Consultant, Division of Medical Sciences, National Cancer Centre, Singapore
Visiting Consultant, National Skin Centre, Singapore
Chairman, Biobanking Subcommittee, Asian Network of Research Resource Centres


Industrial appointments
Member, Diagnostic Hotspot Advisory Panel, Exploit Technologies, A*STAR
Member, Scientific Advisory Board, MiRXES and Invitrocue
Member, Scientific Advisory Board, Invitrocue
Member, Hub Evaluation Panel, Diagnostic Hub, ETPL

Clinical Interest / Subspecialty

•

Clinical Interest
- Diagnostic haematopathology
- Immunodiagnostics and molecular pathology
- Biobanking and medico-legal aspects of pathology
• Subspecialty: Haematopathology

Education

• 1989 MBBS, National University of Singapore, Singapore
•

1999 DipRCPath, Royal College of Pathologists, UK
•

1999 MRCPath, Royal College of Pathologists, UK
•

2007 FRCPath, Royal College of Pathologists, UK
•

1999 DMJ (Path), Society of Apothecaries of London, UK
•

2007 D.Phil (Oxon), Oxford University, UK

Professional / Clinical experience

•

Senior Consultant, Department of Pathology, National University Hospital Mar 2016 – present
•

Senior Consultant, Department of Pathology, Singapore General Hospital 2006- Mar 2016
•

Consultant, Department of Pathology, Singapore General Hospital July 2004-2006
•

Consultant, Department of Pathology & Laboratory Medicine, Tan Tock Seng Hospital Singapore 2002-2004
•

Associate Consultant, Department of Pathology & Laboratory Medicine, Tan Tock Seng Hospital Singapore 2001-2002
•

Associate Consultant, Department of Forensic Medicine, Institute of Science and Forensic Medicine Apr 1999-2001

•

Medical Officer  Department of Forensic Medicine, Institute of Science and Forensic Medicine Apr 1996-1999

Biomarker discovery in NK- and T-cell lymphomas using whole genome sequencing and gene expression profiling techniques

Immune response to follicular and Hodgkin lymphoma, with focus on regulatory T-cells and macrophage subsets in prognostication

Pathology of Type II Enteropathy associated T-cell lymphoma

Genetic alterations in human lymphoid neoplasms with focus on Asian follicular lymphomas and double-hit lymphomas

1. Tan SY, Ooi AS, Ang MK, Koh M, Wong JC, Dykema K, Ngeow J, Loong S, Gatter K, Tan L, Lim LC, Furge K, Tao M, Lim ST, Loong F, Cheah PL, Teh BT. Nuclear expression of MATK is a novel marker of type II enteropathy-associated T-cell lymphoma. Leukemia. 2011 Mar;25(3):555-7.  [JIF: 10.164]
2. Koo GC, Tan SY, Tang T, Poon SL, Allen GE, Tan L, Chong SC, Ong WS, Tay K, Tao M, Quek R, Loong S, Yeoh KW, Yap SP, Lee KA, Lim LC, Tan D, Goh C,Cutcutache I, Yu W, Young Ng CC, Rajasegaran V, Heng HL, Gan A, Ong CK, Rozen S, Tan P, Teh BT, Lim ST. Janus Kinase 3-Activating Mutations Identified in Natural Killer/T-cell Lymphoma. Cancer Discov. 2012 Jul;2(7):591-597. [JIF: 15.929]
3. Tan SY, Chuang SS, Tang T, Tan L, Ko YH, Chuah KL, Ng SB, Chng WJ, Gatter K, Loong F, Liu YH, Hosking P, Cheah PL, Teh BT, Tay K, Koh M, Lim ST. Type II EATL (Epitheliotropic Intestinal T-cell Lymphoma): a neoplasm of intra-epithelial T-cells with predominant CD8aa phenotype. Leukemia. 2013 Aug;27(8):1688-96. [JIF: 10.164]
4. Tan D, Tan SY, Lim ST, Kim SJ, Kim WS, Advani R, Kwong YL. Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines. Lancet Oncol. 2013 Nov;14(12):e548-61. [JIF:25.12]
5. Chen Y, Tan SY, Petersson BF, Khor YM, Gopalakrishnan SK, Tan D. Occult recurrence of monomorphic epitheliotropic intestinal T-cell lymphoma and the role of MATK gene expression in diagnosis. Hematol Oncol. 2016 Mar 7. doi: 10.1002/hon.2288. [Epub ahead of print] [JIF: 3.084]
6. Nairismägi ML, Tan J, Lim JQ, Nagarajan S, Ng CC, Rajasegaran V, Huang D, Lim WK, Laurensia Y, Wijaya GC, Li ZM, Cutcutache I, Pang WL, Thangaraju S, Ha J, Khoo LP, Chin ST, Dey S, Poore G, Tan LH, Koh HK, Sabai K, Rao HL, Chuah KL, Ho YH, Ng SB, Chuang SS, Zhang F, Liu YH, Pongpruttipan T, Ko YH, Cheah PL, Karim N, Chng WJ, Tang T, Tao M, Tay K, Farid M, Quek R, Rozen SG, Tan P, Teh BT, Lim ST, Tan SY, Ong CK. JAK-STAT and G-protein-coupled receptor signaling pathways are frequently altered in epitheliotropic intestinal T-cell lymphoma. Leukemia. 2016 Feb 8. doi: 10.1038/leu.2016.13. [Epub ahead of print] [JIF: 10.431]
7. Dulloo I, Phang BH, Othman R, Tan SY, Vijayaraghavan A, Goh LK, Martin-Lopez M, Marques MM, Li CW, Wang Y, Marín MC, Xian W, McKeon F, Sabapathy K. Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome. Nat Cell Biol. 2015 Apr;17(4):511-23. [JCI: 20.058]
8. Koh CM, Bezzi M, Low DHP, Ang WX, Teo SX, Gay FPH,  Al-Haddawi M, Tan SY, Osato M, Sabo A, Amati B, Wee KB, Guccione E. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 2015 May 11. doi: 10.1038/nature14351. (in press) [JIF: 42.351]
9. Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, Tay K, Lim ST, Lee YS, Kumar SG, Ng SC, Fadilah S, Kim WS, Goh YT; SGH651 investigators. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015 Aug;2(8):e326-33. doi: 10.1016/S2352-3026(15)00097-6. Epub 2015 Jul 7.
10. Dewaele M, Tabaglio T, Willekens K, Bezzi M, Teo SX, Low DH, Koh CM, Rambow F, Fiers M, Rogiers A, Radaelli E, Al-Haddawi M, Tan SY, Hermans E, Amant F, Yan H, Lakshmanan M, Koumar RC, Lim ST, Derheimer FA, Campbell RM, Bonday Z, Tergaonkar V, Shackleton M, Blattner C, Marine JC, Guccione E. Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth. J Clin Invest. 2016 Jan 4;126(1):68-84. doi: 10.1172/JCI82534. Epub 2015 Nov 23.